Pharvaris (PHVS) Operating Expenses (2020 - 2026)
Pharvaris' (PHVS) quarterly Operating Expenses came in at -$51.8 million in Q1 2026, down 16.8% YoY from -$62.3 million in Q1 2025, and up 6.45% on a QoQ basis from -$55.4 million in Q4 2025.
Pharvaris (PHVS) Operating Expenses (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Operating Expenses data on file, last reported at -$51.8 million in Q1 2026.
- Quarterly Operating Expenses fell 16.8% year-over-year to -$51.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$199.3 million (down 16.41% YoY) and the FY2025 annual result came in at -$191.9 million, down 21.68% from the prior year.
- Operating Expenses rose to -$51.8 million in Q1 2026, from -$55.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $179.3 million in Q4 2023 to a low of -$55.4 million in Q4 2025.
- A 5-year average of -$12.5 million and a median of -$30.8 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses advanced 17.27% — and 2024, when it slumped 126.87%.
- Tracing PHVS's Operating Expenses over 5 years: stood at $152.9 million in 2022, then grew by 17.27% to $179.3 million in 2023, then tumbled by 126.87% to -$48.2 million in 2024, then decreased by 14.99% to -$55.4 million in 2025, then climbed by 6.45% to -$51.8 million in 2026.
- The last three Operating Expenses figures came in at -$51.8 million (Q1 2026), -$55.4 million (Q4 2025), and -$46.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | 59.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.03 Mn |
| Mar 31, 2026 | -51.83 Mn |
| Dec 31, 2025 | -55.41 Mn |
| Sep 30, 2025 | -46.37 Mn |
| Jun 30, 2025 | -45.70 Mn |
| Mar 31, 2025 | -44.38 Mn |
| Dec 31, 2024 | -48.19 Mn |
| Sep 30, 2024 | -41.63 Mn |
| Jun 30, 2024 | -37.03 Mn |
| Mar 31, 2024 | -30.76 Mn |
| Dec 31, 2023 | 179.30 Mn |
| Sep 30, 2023 | -28.52 Mn |
| Jun 30, 2023 | -24.45 Mn |
| Mar 31, 2023 | -22.62 Mn |
| Dec 31, 2022 | 152.90 Mn |
| Sep 30, 2022 | -22.57 Mn |
| Jun 30, 2022 | -22.82 Mn |
| Mar 31, 2022 | -21.75 Mn |
| Dec 31, 2021 | 43,355.10 Bn |
| Sep 30, 2021 | -15.72 Mn |